CNIO - Spanish National Cancer Research Centre
Jiangchuan (Harry) H. is a researcher at CNIO - Spanish National Cancer Research Centre, focusing on genetic and molecular epidemiology related to pancreatic cancer since October 2020. Currently serving as an Associate Editor for Wiley, Jiangchuan covers topics in public health, healthcare policy, and epidemiology starting February 2024. Earlier experience includes consulting for Clinton Health Access Initiative, Inc. on tuberculosis screening and diagnostic tools, and for Frost & Sullivan in the life-science industry, specializing in immunotherapy and pharmaceutical development. Jiangchuan also contributed as a research assistant at various institutions, including Karolinska Institutet and Xi'an Jiaotong-Liverpool University, while holding an organized approach to strategic development during an internship at McKinsey & Company. Jiangchuan holds a Master of Medical Science in Epidemiology from Karolinska Institutet and a Bachelor of Science in Pharmacology from China Pharmaceutical University, complemented by exchange studies at McGill University and The University of British Columbia.
This person is not in any teams
CNIO - Spanish National Cancer Research Centre
The Spanish National Cancer Research Centre is a public institution of excellence committed to research, diagnosis and treatment for cancer. The CNIO currently houses 22 Research Groups, organised in 7 Scientific Programmes, plus 5 Clinical Research Unit(s) that work closely with several hospitals. These scientific groups are supported by 19 Core Units that provide state-of-the-art facilities and technical expertise. The CNIO also has an Experimental Therapeutics Programme leader in academic drug discovery. Since 2011, CNIO is recognised a one of the ‘Severo Ochoa’ Centres of Excellence by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación -------------------------------- El Centro Nacional de Investigaciones Oncológicas (CNIO) es una institución pública española dedicada a la investigación, diagnóstico y tratamiento del cáncer. El CNIO cubre todo el recorrido de la I+D+i, desde la investigación básica hasta la clínica. Actualmente el CNIO tiene 22 Grupos de Investigación, organizados en 7 Programas Científicos, más 5 Unidades de Investigación Clínica que trabajan estrechamente con varios hospitales. En el CNIO hay 19 Unidades de Apoyo a la Investigación dotadas de las más modernas instalaciones y conocimientos técnicos. El CNIO también tiene un Programa de Terapias Experimentales de referencia en el descubrimiento de nuevos fármacos. Desde el 2011, el CNIO es uno de los Centros de Excelencia Severo Ochoa acreditados por la Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación.